Traphagen Investment Advisors LLC Has $490,000 Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Traphagen Investment Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 51.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 688 shares of the biopharmaceutical company’s stock after purchasing an additional 233 shares during the period. Traphagen Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $490,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Sheets Smith Wealth Management grew its stake in Regeneron Pharmaceuticals by 4.0% in the 4th quarter. Sheets Smith Wealth Management now owns 1,160 shares of the biopharmaceutical company’s stock valued at $826,000 after buying an additional 45 shares during the last quarter. Enclave Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 31.5% during the fourth quarter. Enclave Advisors LLC now owns 392 shares of the biopharmaceutical company’s stock valued at $279,000 after acquiring an additional 94 shares during the period. Atomi Financial Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 7.0% in the fourth quarter. Atomi Financial Group Inc. now owns 615 shares of the biopharmaceutical company’s stock valued at $438,000 after purchasing an additional 40 shares during the last quarter. Clear Harbor Asset Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 124.5% in the fourth quarter. Clear Harbor Asset Management LLC now owns 5,421 shares of the biopharmaceutical company’s stock worth $3,862,000 after purchasing an additional 3,006 shares during the period. Finally, Aspiriant LLC increased its stake in shares of Regeneron Pharmaceuticals by 14.5% in the fourth quarter. Aspiriant LLC now owns 387 shares of the biopharmaceutical company’s stock worth $276,000 after purchasing an additional 49 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 0.9 %

Shares of REGN opened at $687.80 on Wednesday. The business’s 50 day simple moving average is $735.72 and its 200-day simple moving average is $946.39. Regeneron Pharmaceuticals, Inc. has a one year low of $666.25 and a one year high of $1,211.20. The company has a market capitalization of $75.58 billion, a P/E ratio of 17.02, a PEG ratio of 1.61 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Analyst Ratings Changes

A number of analysts have issued reports on REGN shares. Leerink Partners reaffirmed a “market perform” rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Morgan Stanley dropped their price objective on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price for the company. Finally, Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $1,015.38.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.